ArticleRespiratory research2026
CPSF6-mediated alternative polyadenylation of RUNX1 to regulate silica-induced pulmonary fibrosis progression.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPulmonary fibrosis occurs when myofibroblasts and the extracellular matrix (ECM) excessively accumulate in the lung interstitium. Detailed studies elucidating the role of cleavage and polyadenylation-specific factor 6 (CPSF6) during fibroblast-myofibroblast transition (FMT) remain limited.
methodsA silica-induced mouse pulmonary fibrosis model and a transforming growth factor-β1 (TGF-β1) induced fibroblast activation model were performed to investigate the role and mechanism of CPSF6. The expression of CPSF6 and profibrotic markers was determined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis, Western blotting, and immunofluorescence assays. Dual-luciferase reporter gene assays and RNA immunoprecipitation (RIP) assays were performed to investigate the association between RUNX1 3' untraslated region (3′UTR) and miR-30a-5p.
resultsCPSF6 was downregulated in silica-induced murine fibrotic lung tissues and primary fibroblasts. Silencing CPSF6 via adeno-associated virus (AAV) in vivo exacerbated pulmonary fibrosis, while ectopic CPSF6 expression mitigated the condition. TGF-β1 effectively decreased CPSF6 expression in fibroblasts (MRC-5 and mouse primary lung fibroblast). CPSF6 overexpression blocked the profibrotic effect of TGF-β1, while inhibition of CPSF6 was found to trigger FMT. Notably, Runt-related transcription factor 1 (RUNX1), a crucial transcription factor implicated in fibrosis, was identified as a downstream effector of CPSF6. Mechanistically, CPSF6 loss favored the utilization of the proximal poly (A) site in the 3'UTR of RUNX1, leading to the production of a short 3'UTR RUNX1 transcript and more protein by avoiding being targeted for degradation by miR-30a-5p.
conclusionsCPSF6 is implicated in the pathogenesis of fibrosis through its function in fibroblast activation, thereby enhancing the mechanistic understanding of fibrotic progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.